Basil Health Ventures

Clinical precision applied to every investment.

We are a Cambridge-based venture firm backing founders building diagnostic and digital-health infrastructure that actually works — tested against clinical realities before we write a check.

$75M
Assets Under Management
2
Funds Closed
8
Portfolio Companies
2019
Founded
Portfolio

Eight companies. One diagnostic hypothesis.

We invest at Seed and Series A in companies building tools that make clinical diagnoses more precise, faster, or accessible — with a recurring emphasis on AI-enabled imaging, computational biology, and health infrastructure.

View all portfolio companies →
Cleerly
Cardiovascular AI Imaging
Series A · 2020
Cofactor Genomics
RNA Diagnostics for Oncology
Series A · 2021
Iterative Health
AI-Endoscopy Diagnostic Devices
Series A · 2022
Arpeggio Bio
Computational Drug Discovery
Seed · 2022
The Team

Investors who practiced before they invested.

PS
Dr. Priya Sharma
Managing Partner

MD-PhD from Harvard Medical School and MIT. Practiced internal medicine at Mass General before founding Basil Health Ventures in 2019.

HA
Dr. Henry Aaronson
Partner

Former CMO of a digital-therapeutics company (Series B exit). Chief of Endocrinology at a regional academic hospital. MD Johns Hopkins.

EW
Eliza Wen
Principal

PhD Biomedical Engineering, Duke. Six years leading commercial strategy for pharma and medical-device clients at a Boston life-sciences consultancy.

Meet the Partners →